Print

FDA Accepts Biogen Idec, Inc. (Massachusetts) (BIIB)’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A  
5/13/2013 11:06:30 AM

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A. ELOCTATE is the first hemophilia A product candidate in a new class of long-lasting clotting factor therapies being developed with the goal of providing long-lasting protection and reducing the burden of treatment for patients with this chronic condition.
//-->